Translational Research in Academia and Industry

Research that bridges between scientific insights and clinical application is one of the most active and exciting areas of current biomedical activity. Much of this translational work occurs through collaborations between academic and industrial institutions, taking advantage of the respective strengths and resources of the two sectors. However, such collaborations sometimes can be challenging due to differences between the cultures and priorities of the two parties. This article discusses the nature of translational research, with a focus on the academia-industry interface, analyzes the factors important for effective collaborations, and describes specific examples of successful translational research programs.

[1]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2]  G. Giaccone,et al.  EGFR inhibitors: what have we learned from the treatment of lung cancer? , 2005, Nature Clinical Practice Oncology.

[3]  C. Lengauer,et al.  Cancer drug discovery through collaboration , 2005, Nature Reviews Drug Discovery.

[4]  P. Jänne,et al.  Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. , 2005, Cancer research.

[5]  L. Rozamus,et al.  Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. , 2005, Blood.

[6]  K. Nakai,et al.  [Controlling signal transduction with synthetic ligands]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[7]  S. Heimfeld,et al.  Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. , 2004, Blood.

[8]  V. Rivera,et al.  Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. , 1999, Science.

[9]  T. Clackson,et al.  A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. , 2001, Blood.

[10]  T. Clackson,et al.  Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers , 2001, Journal of clinical pharmacology.

[11]  C. von Kalle,et al.  Pharmacologically regulated in vivo selection in a large animal. , 2002, Blood.

[12]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.